Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.

doi:10.1186/s13073-020-00731-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.

Genome medicine - 30 Mar 2020

Reustle Anna, Di Marco Moreno, Meyerhoff Carolin, Nelde Annika, Walz Juliane S, Winter Stefan, Kandabarau Siahei, Büttner Florian, Haag Mathias, Backert Linus, Kowalewski Daniel J, Rausch Steffen, Hennenlotter Jörg, Stühler Viktoria, Scharpf Marcus, Fend Falko, Stenzl Arnulf, Rammensee Hans-Georg, Bedke Jens, Stevanović Stefan, Schwab Matthias, Schaeffeler Elke

Abstract excerpt

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the dominant subtype of renal cancer. With currently available therapies, cure of advanced and metastatic ccRCC is achieved only in rare cases. Here, we developed a workflow integrating different -omics technologies to identify ccRCC-specific HLA-presented peptides as potential drug targets for ccRCC immunotherapy. METHODS: We analyzed HLA-presented peptides...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA Antigens

Share to Hypoxia-Inducible Factor-Proline Dioxygenases

Share to Immunotherapy

Share to Kidney

Share to Kidney Neoplasms

Share to Lymphocyte Activation

Share to Peptide Fragments

Source

Open in PubMed Open full text

Identifiers

PMID: 32228647
DOI: 10.1186/s13073-020-00731-8
PMCID: PMC7106651

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.PMID 32228647Read ↗

Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinomaSemantic proximity Read ↗

Analyzing and validating the prognostic value and immune microenvironment of clear cell renal cell carcinomaSemantic proximity Read ↗

Based on the identification of tumor antigens and immune subtypes in renal clear cell carcinoma for mRNA vaccine developmentSemantic proximity Read ↗

Multi-omics features-based machine learning method improve immunotherapy response in clear cell renal cell carcinomaSemantic proximity Read ↗

Establishment of a Seven-Gene Signature Associated with CD8+ T Cells through the Utilization of Both Single-Cell and Bulk RNA-Sequencing Techniques in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Clear Cell Renal Cell Carcinoma: A Comprehensive in silico Study in Searching for Therapeutic TargetsSemantic proximity Read ↗

Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.Semantic proximity Read ↗

MDK promotes M2 macrophage polarization to remodel the tumour microenvironment in clear cell renal cell carcinomaSemantic proximity Read ↗

Integrated analysis of single-cell and transcriptome based RNA-seq multilayer network and WGCNA for construction and validation of an immune cell-related prognostic model in clear cell renal cell carcinomaSemantic proximity Read ↗

TDERS, an exosome RNA-derived signature predicts prognosis and immunotherapeutic response in clear cell renal cell cancer: a multicohort studySemantic proximity Read ↗

CRISPR/Cas9-based discovery of ccRCC therapeutic opportunities through molecular mechanism and immune microenvironment analysisSemantic proximity Read ↗

Identification of a Novel Immune-Related Prognostic Biomarker and Small-Molecule Drugs in Clear Cell Renal Cell Carcinoma (ccRCC) by a Merged Microarray-Acquired Dataset and TCGA DatabaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.